那格列奈联合门冬胰岛素30治疗单独胰岛素控制不良的2型糖尿病

Treatment of type 2 diabetes mellitus with combined use of nateglinide and novorapid 30 in patients poorly controlled with novorapid 30 therapy

目的评价那格列奈联合门冬胰岛素30(N30)治疗胰岛素控制不良的2型糖尿病(T2DM)的有效性和安全性。方法 40例T2DM患者均分为单用N30治疗(N组)和加用那格列奈治疗(NN组)。NN组在胰岛素治疗的基础上,于中餐前加服那格列奈120mg,疗程1个月。结果与N组相比,NN组中餐后血糖、糖化血红蛋白控制更理想,且低血糖反应少。结论对接受N30治疗而中餐后血糖仍不达标的T2DM患者,那格列奈是个良好的备选降糖药。

Objective To evaluate the efficacy of combined nateglinide and novorapid 30 in treating type 2 diabetes mellitus（T2DM）patients poorly controlled with novorapid 30 alone.MethodsFourty T2DM patients were treated with novorapid 30 alone（group N,20 cases）and with additional nateglinide 120mg given before lunch（group NN）.The course of treatment was one month.ResultsCompared with group N,the 2-h glucose level after lunch and glycosylated hemoglobin 1c（HbA1c）were better controlled with less hypoglycemic events in group NN.Conclusion Nateglinidre is a better choice in T2DM patients whith poorly controlled glucose level after lunch with novorapid 30.